Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Jul 2025 07:00 AM
RNS
Collaboration Agreement with Voxcell BioInnovation
30 Jun 2025 03:48 PM
RNS
Result of AGM
20 Jun 2025 07:00 AM
RNS
Ambrose Exercise Option on VAL401
09 Jun 2025 10:57 AM
RNS
ValiRx Investor Webinar
06 Jun 2025 10:54 AM
RNS
Holding(s) in Company
06 Jun 2025 07:00 AM
RNS
Final Results & Notice of AGM
03 Jun 2025 07:00 AM
RNS
New Evaluation and Material Transfer Agreement
20 May 2025 01:25 PM
RNS
Holding(s) in Company
12 May 2025 07:00 AM
RNS
Inaphaea Deal Extension With Dominion
30 Apr 2025 07:00 AM
RNS
Commercial Update
03 Apr 2025 07:00 AM
RNS
Termination of Letter of Intent with TheoremRx
27 Mar 2025 07:00 AM
RNS
Directorate Changes and new Advisory Board
21 Mar 2025 11:07 AM
RNS
Director Disclosure Update
24 Feb 2025 07:00 AM
RNS
Conclusion of Evaluation Project
03 Feb 2025 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
30 Jan 2025 07:00 AM
RNS
Extension of Evaluation Agreement
29 Jan 2025 07:00 AM
RNS
New Evaluation and Option Agreement
15 Jan 2025 12:47 PM
RNS
Holding(s) in Company
15 Jan 2025 11:29 AM
RNS
Holding(s) in Company
14 Jan 2025 07:00 AM
RNS
Holding(s) in Company
09 Jan 2025 11:37 AM
RNS
Holding(s) in Company
09 Jan 2025 11:14 AM
RNS
Holding(s) in Company
08 Jan 2025 07:00 AM
RNS
Holding(s) in Company
02 Jan 2025 11:45 AM
RNS
Holding(s) in Company
31 Dec 2024 01:06 PM
RNS
Holding(s) in Company
31 Dec 2024 08:39 AM
RNS
Update on proposed sub-license of VAL201
30 Dec 2024 01:30 PM
RNS
Result of GM, Issue of Equity, Warrants and TVR
20 Dec 2024 07:00 AM
RNS
ValiRx launches new interactive investor website
10 Dec 2024 04:45 PM
RNS
Broker Offer Results & Director/PDMR Subscription
10 Dec 2024 03:03 PM
RNS
Posting of Circular and Notice of General Meeting
09 Dec 2024 07:00 AM
RNS
Conditional Fundraising & Launch of Broker Offer
22 Nov 2024 07:00 AM
RNS
Inaphaea award of HEIF Funding and PhD sponsorship
20 Nov 2024 07:00 AM
RNS
Update on proposed sub-license of VAL401
19 Nov 2024 07:00 AM
RNS
Contract Award
18 Nov 2024 07:00 AM
RNS
First Sale of New Product Line
30 Oct 2024 07:00 AM
RNS
Update on proposed sub-license of VAL201
18 Oct 2024 07:00 AM
RNS
Directorate Change
14 Oct 2024 07:00 AM
RNS
Investor Webinar
07 Oct 2024 07:00 AM
RNS
Inaphaea Co-Marketing Agreement
27 Sep 2024 07:00 AM
RNS
Half-year Report
26 Sep 2024 07:00 AM
RNS
Conclusion of Evaluation Project
24 Sep 2024 07:00 AM
RNS
Inaphaea Co-Marketing Agreement
18 Sep 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
16 Sep 2024 07:00 AM
RNS
Inaphaea Co-Marketing Agreement
09 Sep 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
09 Sep 2024 07:00 AM
RNS
Investor Evening
27 Aug 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
12 Aug 2024 07:00 AM
RNS
Directorate Change
25 Jul 2024 07:00 AM
RNS
Directorate Changes
03 Jul 2024 08:51 AM
RNS
Proposed Director Appointment

ValiRx is a fast-growing drug development company focused on identifying novel science with high potential for successful development into products that improve the lives of patients throughout treatment.

ValiRx share price listed on AIM in 2004 under the ticker VAL.

UK 100

Latest directors dealings